vimarsana.com

Page 258 - புதியது ப்ராடக்ட்ஸ் மற்றும் சேவைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

12-Month Data from Surmodics TRANSCEND Trial Presented at LINC 2021 Event

AB Science announces that a new independent publication confirms that masitinib has anti-vital

Press release content from Globe Newswire. The AP news staff was not involved in its creation. AB Science announces that a new independent publication confirms that masitinib has anti-vital . AB ScienceJanuary 25, 2021 GMT NEW INDEPENDENT PUBLICATION CONFIRMS THAT MASITINIB HAS ANTI-VIRAL ACTIVITY AGAINST THE SARS-COV-2 VIRUS IN VITRO AND IS A PROMISING CANDIDATE FOR TREATING COVID-19 Paris, 25 January 2021, 8.30am CET AB Science SA (NYSE Euronext - FR0010557264 - AB) today announced the publication of preclinical study results with masitinib in COVID-19. Research led by scientists from the Institute of Human Virology (Guangzhou, China) has been published in the peer-reviewed journal mBIO (a journal of the American Society for Microbiology). The article, entitled ‘Engineering a reliable and convenient SARS-CoV-2 replicon system for analysis of viral RNA synthesis and screening of antiviral inhibitors’,[1] is freely accessible online from the mBio journal site https://mb

Kimberly-Clark Announces Year-End 2020 Results And 2021 Outlook

Press release content from PR Newswire. The AP news staff was not involved in its creation. Kimberly-Clark Announces Year-End 2020 Results And 2021 Outlook January 25, 2021 GMT DALLAS, Jan. 25, 2021 /PRNewswire/ Kimberly-Clark Corporation (NYSE: KMB) today reported year-end 2020 results and provided its 2021 outlook. Executive Summary Fourth quarter 2020 net sales of $4.8 billion increased 6 percent compared to the year-ago period, including organic sales growth of 5 percent. Full-year 2020 net sales of $19.1 billion increased 4 percent, with organic sales up 6 percent. Diluted net income per share for the fourth quarter was $1.58 in 2020 and $1.59 in 2019. Full-year diluted net income per share was $6.87 in 2020 and $6.24 in 2019. Fourth quarter adjusted earnings per share were $1.69 in 2020 compared to $1.71 in 2019. Adjusted earnings per share exclude certain items described later in this news release.

Western Europe Brewing Waste Market and the Impact of COVID-19 in the Medium Term

Press release content from Business Wire. The AP news staff was not involved in its creation. Western Europe Brewing Waste Market and the Impact of COVID-19 in the Medium Term - ResearchAndMarkets.com January 25, 2021 GMT DUBLIN (BUSINESS WIRE) Jan 25, 2021 This report presents a strategic analysis of the brewing waste market in Western Europe and a forecast for its development in the medium term, taking into account the impact of COVID-19 on it. It provides a comprehensive overview of the market, its dynamics, structure, characteristics, main players, trends, growth and demand drivers, etc. ADVERTISEMENT The purpose of the report is to describe the state of the brewing waste market in Western Europe, to present actual and retrospective information about the volumes, dynamics, structure and characteristics of production, imports, exports and consumption and to build a forecast for the market in the next five years, taking into account the impact of COVID-19 on it. In addition,

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.